Skip to main content
SpringerLink
Log in

Rivaroxaban versus aspirin: more bleeding, no more benefit

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source

Reference

  • Hart RG et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine : 16 May 2018. Available from: URL: http://dx.doi.org/10.1056/NEJMoa1802686

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivaroxaban versus aspirin: more bleeding, no more benefit. Reactions Weekly 1703, 8 (2018). https://doi.org/10.1007/s40278-018-46383-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-46383-x

Search

Navigation